[
  {
    "ts": null,
    "headline": "JPM26: Edwards Lifesciences targets 10% growth in 2026",
    "summary": "Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.",
    "url": "https://finnhub.io/api/news?id=ab7ce53a4fed6a8c6f93709600d41f0ffe5401f19ada2357b22946107b38df27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768414783,
      "headline": "JPM26: Edwards Lifesciences targets 10% growth in 2026",
      "id": 138114849,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.",
      "url": "https://finnhub.io/api/news?id=ab7ce53a4fed6a8c6f93709600d41f0ffe5401f19ada2357b22946107b38df27"
    }
  },
  {
    "ts": null,
    "headline": "Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?",
    "summary": "EW benefits from strong TAVR and TMTT momentum, but macro pressures and FX headwinds cloud the near-term outlook.",
    "url": "https://finnhub.io/api/news?id=028621b8fa3bb06f5d0e8bd5efc4c1e4ffcd2b3284c15cab949231ad89f35fd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768395000,
      "headline": "Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?",
      "id": 138111962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "EW benefits from strong TAVR and TMTT momentum, but macro pressures and FX headwinds cloud the near-term outlook.",
      "url": "https://finnhub.io/api/news?id=028621b8fa3bb06f5d0e8bd5efc4c1e4ffcd2b3284c15cab949231ad89f35fd3"
    }
  }
]